Chapter 52: Sexually Transmitted Infections

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, when a patient walks into a clinic with a hacking cough and a fever,

the diagnostic path is usually pretty visible.

Right, yeah.

It's straightforward.

Exactly.

You listen to their lungs, you check their temperature, and you kind of just follow the obvious signs toward an upper respiratory infection.

Yeah, you have a clear roadmap.

But when you step into the world of sexual health,

that visibility totally vanishes.

You're suddenly dealing with, well, an invisible epidemic.

Completely invisible.

We aren't just looking at straightforward pathogens anymore.

You know, we're looking at organisms that have evolved to perfectly exploit both human behavior and our biological blind spots.

It is a massive shift in clinical thinking.

You really have to become a completely different kind of detective.

Yeah, totally.

Because you're dealing with these immense public health challenges,

deep -seated social stigmas, and frankly, microscopic ecosystems inside the human body that are incredibly delicate.

Yeah.

And that is exactly our mission today.

So welcome to the Deep Dive.

We are talking directly to you, the nurse practitioner and advanced practice nursing students out there.

Well, welcome, guys.

Consider this your high -yield, one -on -one tutoring session brought to you by the Last Minute Lecture Team.

That's right.

We're taking a comprehensive look at sexually transmitted infections straight from Chapter 52 of your primary care textbook to help you master this material for your clinical practice.

Because we want to equip you with the actual clinical reasoning you'll need on the floor.

Right.

It is not enough to just, you know, memorize a list of symptoms and medications.

We need to explore how these pathogens operate, how they evade detection, and why our diagnostic and treatment protocols are structured the way they are.

Because the stakes we're dealing with here are remarkably high.

Like the text opens with a statistic that, frankly, stopped me in my tracks.

Oh, the prevalence data.

Yeah.

Right now, one in five Americans is infected with an STI other than HIV.

Just let that sink in for a second for everyone else.

One in five.

And the United States currently has the highest STI rate of any nation in the industrialized world.

It really is a staggering reality.

And I mean, it paints a clear picture of the environment you're about to step into as a clinician.

For sure.

STIs are actually the second most prevalent communicable diseases in the U .S.

sitting right behind those upper respiratory infections we just mentioned.

And the trends are, well, they're moving in the wrong direction.

Yeah.

So let's look at the CDC data highlighted in the text, specifically the spikes from 2017 to 2018.

We saw chlamydia hit an all -time high of 1 .7 million cases.

Which is wild.

Gonorrhea went up 5%, which is the highest number reported since 1991.

But the statistic that signals a truly massive systemic failure.

Is the congenital syphilis.

Yes, congenital syphilis.

We saw a 183 % increase in congenital cases.

That 183 % spike is just a devastating red flag for maternal fetal health.

Wait, 183%, that's not a typo.

Not a typo, it's real.

And you know, congenital syphilis can lead to stillbirth,

severe neurological deficits, and these catastrophic bone deformities in infants.

Oh wow.

Yeah, it directly mirrors the rising rates of primary and secondary syphilis we're catching, or really failing to catch in females of childbearing age.

It basically tells us that our primary care screening nets have gaping holes in them.

So before we can even talk about how to treat these infections, we need to know who is most vulnerable to help the students build their index of suspicion.

The data shows that almost 50 % of all STIs in the U .S.

occur in the 15 -24 age group.

We constantly hear about the behavioral risks for teenagers and young adults, multiple partners, lack of barrier methods, general risk taking.

But the text makes a point to emphasize biological susceptibility.

What exactly makes a 19 -year -old biologically more vulnerable to an infection than, say, a 30 -year -old?

It comes down to cervical anatomy, which is crucial for an APN to visualize.

In young females, there's a specific area on the ectocervix called the squamacolumnar junction.

The squamacolumnar junction.

Right.

This is where two different types of cervical cells meet.

During adolescence and early adulthood,

this cellular junction is very prominent and exposed.

The cells here are highly active.

They're undergoing constant change, making them incredibly permeable.

So pathogens like chlamydia and HPV essentially view this exposed junction as a wide open target.

So it's not just about behavior.

I mean, their anatomy is physically leaving the door unlocked.

Precisely.

And if we fail to recognize these infections early, the downstream effects are severe.

Untreated STIs in female patients frequently ascend into the uterus and fallopian tubes, causing pelvic inflammatory disease, or PID.

Right.

And that massive inflammatory cascade leaves behind fibrotic scar tissue.

Yeah.

And that scar tissue can physically block the fertilized egg, which leads to life -threatening ectopic pregnancies, or it can cause permanent infertility.

And we see severe consequences in male patients as well, right?

Absolutely.

Untreated infections can travel up the urogenital tract, causing epididymitis, prostatitis, and this state of chronic inflammation that actively increases the long -term risk of developing prostate cancer.

Furthermore, for anyone who contracts syphilis and goes untreated, the disease can progress to the tertiary stage.

The really bad stage.

Yeah.

This involves severe central nervous system damage, cardiovascular collapse, and the development of these nodular lesions called gummas that destroy skin, bone, and internal organs.

Those complications are terrifying, which makes rapid, accurate diagnosis your absolute top priority.

So let's get into the clinical assessment of the core pathogens from the text.

Let's do it.

Let's start with bacterial vaginosis, or BV, and trichomoniasis.

Now a key distinction to keep in mind, BV is not technically considered a transmissible STI.

Right.

That's an important distinction.

It's a pH -driven overgrowth of vaginal microflora.

But it is heavily linked to sexual activity because of how that activity alters the vaginal pH.

When a patient presents with symptoms, your brain needs to immediately run through the AMSL criteria to diagnose BV.

Okay.

The AMSL criteria.

You need three of the following four indicators.

First, the presence of clue cells on a saline smear.

Second, a vaginal pH greater than 4 .5.

Got it.

Third, a thin gray homogenous discharge.

And fourth, a positive whiff test.

Let's break those down really quickly.

What exactly are we looking for when we say clue cells?

Good question.

A clue cell is a vaginal epithelial cell that's so heavily dusted with overgrown bacteria that its outer borders become completely blurred and stippled under the microscope.

Oh, it gets covered in sand.

Exactly.

If you see those, along with an elevated pH and that characteristic gray discharge, you perform the whiff test by adding 10 % potassium hydroxide to the sample.

And what does that do?

If it releases a strong fishy amine odor, you have your diagnosis and the standard treatment is metronidazole.

And here is a massive red flag for patient education, for all the students listening.

You must explicitly warn your patient that there is absolutely no alcohol consumption allowed while taking metronidazole.

None.

Zero.

Why is that interaction so severe?

Because metronidazole blocks the body's ability to properly break down alcohol.

Specifically, it stops the breakdown of acetaldehyde.

If a patient drinks alcohol, that toxic acetaldehyde rapidly builds up in their system, triggering a severe disulfiram -like reaction.

Oh, that sounds awful.

We are talking intense flushing, violent nausea and vomiting, palpitations and severe headaches.

A miserable experience that is entirely preventable with good counseling.

Exactly.

Now compare BV to trichomoniasis.

Trich is a transmissible protozoan parasite.

It also causes pH changes and can be treated with metronidazole, but the clinical presentation is different.

Right.

The discharge for trich is typically yellow -green and frothy.

Moving on to the bacterial heavyweights, syphilis, chlamydia and gonorrhea.

Syphilis, which is caused by the bacterium trypanema pallidum, operates in distinct stages.

Right.

Primary syphilis typically presents as a painless ulcer called a chancre at the site of infection.

Wait.

Painless?

Usually completely painless, which is why it's missed.

Secondary syphilis manifests later as a systemic maculopapular rash, famously appearing on the palms of the hands and the soles of the feet.

And tertiary, as we covered, is the destructive neurological and cardiac phase.

And the diagnostic reasoning for syphilis is fascinating because it requires a two -step process.

First, you run a non -troponemal test, like a VDRL or RPR.

If that comes back positive, you must follow it up with a troponemal test, like the FDA ABS, to confirm it.

The reason for that two -step dance is specificity.

The initial RPR or VDRL is essentially casting a wide net.

Right.

It detects biomarkers released during cellular damage, making it a fast and cheap screening tool.

However, that wide net can easily catch false positives from things like autoimmune diseases or even pregnancy.

Oh, so it's not specific to the bug itself.

Right.

The FDA ABS test is your microscopic zoom -in.

It specifically looks for antibodies created to fight the actual troponema bacteria.

Once you confirm it, the standard treatment is an intramuscular injection of benzothene penicillin G.

Okay, let's look at chlamydia and gonorrhea next.

These two pathogens are notorious for co -infecting patients, so you will frequently see them addressed together.

How are we actually dosing these therapies in the clinic based on the CDC guidelines in the text?

For gonorrhea, the primary therapy requires a very aggressive dual approach.

You administer a 250 -milligram intramuscular injection of ceftriaxone combined with one gram of azithromycin given orally in a single dose.

So you're hitting it from two sides.

You're hitting it with two different mechanisms of action.

Now, if you are treating chlamydia alone, the standard regimen is either that one gram of oral azithromycin in a single dose or doxycycline 100 milligrams orally twice a day for seven days.

We also need to factor in the viral STIs, which fundamentally change the patient's long -term health landscape.

Yeah, they do.

HPV is the most common viral STI, and there are over 200 different serotypes.

The critical clinical distinction is that 14 of those serotypes are considered high -risk and oncogenic.

Meaning, they have the potential to cause cervical, vaginal, penile, or oropharyngeal cancers.

Right.

And the low -risk serotypes are the ones responsible for intergeneral warts.

We also have HSV, or herpes simplex virus, which presents with incredibly painful vesicular or ulcerated lesions, contrasting sharply with the painless chancre of primary syphilis we talked about.

Ouch, yeah.

HSV is managed long -term with antiviral medications like acycliver or valacycliver.

Finally, there is HIV, which actively attacks and destroys the immune system.

Without intervention, it progresses to AIDS over a period of two to 10 years.

It's wild that a single dose of azithromycin can completely clear a chlamydia infection.

But it really makes you wonder, if these bacterial pathogens are so easily killed by standard antibiotics, how are they bypassing the body's natural defenses so successfully in the first place?

To understand that, we have to look closely at the pathophysiology of the reproductive tract.

Let's start with male anatomy.

You might assume that the physical length of the male urethra provides a robust barrier against infection.

However, the primary vulnerability actually lies on the outer skin of the penile shaft.

Skin itself.

Yeah.

During sexual activity, microscopic abrasions form on the skin.

These micro abrasions act as direct, microscopic entryways, allowing pathogens to completely bypass the epithelial barrier and enter the tissues.

And the female reproductive tract has a brilliant, though delicate,

natural defense system.

It relies on maintaining a very low acidic pH, driven by the presence of normal, healthy microflora, specifically lactobacillus.

Yes.

These bacteria produce hydrogen peroxide, which creates a hostile environment for pathogens.

I always like to picture the lactobacillus and the vaginal microbiome as like a team of strict bouncers at a nightclub, actively pushing the dangerous gram -negative bacteria out the door.

I love that analogy.

It is an incredibly effective system right up until it gets disrupted.

Vaginal pH can be thrown off balance by a multitude of factors.

Hormonal fluctuations, exposure to semen, underlying diseases like diabetes, or even normal aging.

And what happens when a patient is prescribed a broad -spectrum antibiotic for something entirely unrelated like a sinus infection, or if they regularly use vaginal douches?

They're essentially firing the bouncers.

The antibiotics wipe out the protective lactobacillus, the acidic pH rises, the club doors swing wide open,

and opportunistic pathogens like BV or yeast move right in to take over the environment.

We talked earlier about how young females are vulnerable because of that prominent squamous columnar junction, but as patients age, the biological vulnerabilities shift dramatically, don't they?

They do.

To stick with your analogy, in older female patients, the bouncers might still be there, but the physical walls of the club are getting weaker.

Aging and the drop in estrogen lead to the thinning and drying of the vaginal mucosa and vulva tissue.

This compromises the physical barrier itself, making the tissues much more susceptible to the microtears that allow pathogens to enter.

The text also highlights a truly terrifying synergistic effect between these infections.

Having one STI actually amplifies your risk of contracting another, particularly HIV.

The mucosal inflammation and the physical sores caused by one infection basically act as an open invitation, rolling out the red carpet for HIV to enter the bloodstream.

Which brings us directly to the assessment phase.

How do you actually uncover these infections in the exam room when the pathogens are so good at hiding?

Subjectively, the most vital concept to grasp is that the vast majority of STIs are completely asymptomatic.

The World Health Organization notes that symptoms are often so mild they go entirely ignored by the patient.

When symptoms do occasionally prompt a clinical visit, patients might report lower pelvic pain, dysuria, pain during intercourse, or abnormal bleeding.

But I want to focus on a specific demographic that the text identifies as a massive clinical blind spot during subjective assessment.

Yes, this is such a critical point.

STI incidence is rising sharply in older adults.

Part of this is driven by the widespread availability of erectile dysfunction medications, keeping adults sexually active longer, combined with a stark lack of condom use.

The data shows only one in five sexually active older adults actually uses barrier protection.

But the primary issue isn't just the behavior, it's the provider bias.

Clinicians simply fail to associate an older adult's presenting symptoms with a possible STI.

Let me pose a real -world dilemma on behalf of the students.

If an 85 -year -old patient comes into the clinic complaining of burning with urination,

a student's absolute first instinct is going to be a standard urinary tract infection.

Of course it is.

How do we respectfully pivot to an STI assessment without making the patient feel accused or alienated?

You do it by completely normalizing the process.

You blame the protocol, not the patient.

Oh, I like that.

You look at them and say, Mrs.

Smith, whenever any patient comes in with these specific urinary

My standard clinic protocol is to check for a UTI, but we also run a routine strain for infections like chlamydia or gonorrhea because the symptoms can look completely identical under the microscope.

That's perfect.

You make it a seamless stigma -free part of your universal diagnostic workout.

That framing is so helpful.

So moving to objective findings,

what are we looking for during the physical exam?

Well for a female patient, a speculum exam is essential to inspect the vaginal walls, the cervix, and the nature of any discharge.

Normal discharge is usually clear or white.

If you observe a thin gray discharge, your mind should jump to BV, and that's when you perform your potassium hydroxide whiff test.

If the discharge is yellow -green and frothy, you are highly suspicious of trichomoniasis.

You also need to perform a careful bimanual exam, assessing the size and mobility of the uterus and checking for adnexal tenderness.

Yes, and what you're specifically feeling for is cervical motion tenderness, sometimes called the chandelier sign.

This occurs when moving the inflamed cervix pulls on the surrounding infected pelvic organs, causing severe pain.

If present, it is a massive red flag indicating the infection has ascended and the patient likely has pelvic inflammatory disease.

In male patients, your objective assessment includes palpating the testes, the epididymis, and the lower abdomen for any signs of swelling or tenderness.

If prostatitis is suspected,

a digital rectal exam is required to directly assess the prostate gland.

Right.

And for all patients, regardless of gender, any pink -red maculopapular rashes or firm nodular skin lesions should immediately trigger an evaluation for syphilis.

Those assessment findings lead directly into your clinical reasoning and differential diagnosis.

Let's look at the USPSTF screening guidelines.

Who are we routinely testing, even if they're entirely asymptomatic?

Well, for female patients, annual chlamydia and gonorrhea screening is recommended for all sexually active individuals under the age of 25, as well as older patients with high risk factors.

Syphilis screening is absolutely mandatory during the first prenatal visit to prevent that devastating congenital transmission we discussed.

And routine HIV testing is recommended for everyone between the ages of 13 and 64 seeking care in any clinical setting.

When you execute these tests, the gold standard modality is net nucleic acid amplification testing.

It is FDA approved for identifying chlamydia, gonorrhea, trichomonas, and HSV.

Why has net become the absolute gold standard over traditional cultures?

Because of its incredible sensitivity.

Traditional cultures require a relatively large amount of live bacteria to grow in a lab.

Right.

Net Day, on the other hand, actively searches for a tiny microscopic fragment of the pathogen's genetic code, its DNA or RNA, and photocopies it millions of times over until its presence is undeniable.

Wow.

Yeah, it can detect an infection even when the bacterial load is incredibly low.

Net's a phenomenal tool, but as an APN, your clinical reasoning has to start before you ever send a swab to the lab.

You have to build a comprehensive differential diagnosis list.

You really do.

Because if a patient presents with severe lower pelvic pain, locking your brain onto an STI diagnosis too early can be fatal.

Ectopic pregnancies and acute appendicitis can present with the exact same lower pelvic pain and tenderness.

Absolutely.

Missing an ectopic pregnancy while waiting for a chlamydia swab to come back is a catastrophic error.

You must cast a wide net.

Your differential must include UTI,

contact dermatitis, pelvic abscesses, endometriosis, or even toxic shock from a retained tampon.

Safety and priority setting always come first.

Precisely.

You rule out the life -threatening differentials first.

Once you have done that and your net confirms an STI, we transition to evidence -based management.

The ultimate goal here is preventing reinfection, and you cannot do that unless you treat the patient's intimate partners.

This introduces the strategy of expedited partner therapy, or EPT.

EPT is a fascinating public health tool.

It legally allows the provider to write a prescription for the patient's partner without ever seeing or examining the partner in the clinic.

It's incredibly effective at stopping the ping -pong effect, where a treated patient goes home and is immediately reinfected by their untreated partner.

It is essential for managing chlamydia and gonorrhea, but the text highlights a highly specific dilemma regarding EPT for gonorrhea.

Right, because earlier we established that the CDC's primary therapy for gonorrhea requires a robust intramuscular injection of ceftriaxone.

Exactly.

You obviously cannot hand the patient a syringe of ceftriaxone and tell them to go inject their partner at home.

Partner prescriptions can only be written for oral medications.

So to solve this, the CDC endorses using oral syphilisborins for heterosexual partners as part of the EPT protocol.

Let me stop and question that logic for a moment.

We know the pathogen is developing resistance, which is why IM -ceftriaxone is the standard.

Knowingly giving an oral medication that we recognize is suboptimal goes against all our basic pharmacology instincts.

Why is this the clinical standard?

It comes down to a strict public health strategy of harm reduction.

The reality is that the risk of an entirely untreated partner continuing to spread the infection or reinfecting your primary patient and triggering PID poses a far greater danger to the community than the risk of using a suboptimal oral therapy.

It's a calculated necessary compromise to break the chain of transmission.

That makes perfect sense when you look at the bigger public health picture.

What about follow -up care?

Do we need to bring these patients back for a test of cure to prove the pathogen is gone?

For chlamydia and gonorrhea, if you use the approved first -line protocols, a routine test of cure is generally not recommended.

Oh really?

Yeah, unless their symptoms actively persist or you were forced to use an alternative regimen due to an allergy.

Trichomoniasis, however, is a different story.

Right, because of the reinfection rates.

Exactly.

Because the reinfection rates for Trich are notoriously high, the guidelines specifically require bringing the patient back for a retest at the three -month mark.

Beyond prescribing and testing,

an APN has strict legal and collaborative responsibilities.

You are a mandated reporter.

You must report specific infections directly to your state health department, including HIV,

syphilis, gonorrhea, chancroid, and chlamydia.

Yep, it's mandatory.

You're tasked with providing the date of diagnosis, the treatment administered, the patient's pregnancy status, and the details of partner notification.

Which brings us to the final and perhaps the most defining step in your clinical workflow, health promotion.

You have to educate the patient to prevent this from happening again.

We can break this health promotion down into three distinct levels.

Primary prevention focuses on stopping the infection before it ever occurs.

This includes advocating for 100 % condom use, discussing partner limitation, and pushing for vaccinations.

Remember, the HPV vaccine is approved as primary prevention for patients as young as nine years Secondary prevention is all about early detection through routine STI and cervical cancer screenings, catching the microscopic changes before they evolve into full -blown complications.

And tertiary.

And tertiary prevention focuses on strict medication compliance and ensuring those partners are treated to halt the disease progression.

But the text also pauses to deeply consider the management of chronic viral STIs like HPV, HSV, and HIV.

These aren't just a seven -day course of doxycycline.

This is where the true art of advanced practice nursing comes into play.

Your job isn't just accurately swabbing a lesion and writing a script.

It's sitting down and providing compassionate,

empathetic counseling to a patient who has just received a lifelong viral diagnosis.

It's discussing the potential for remission, creating a plan for managing future outbreaks and connecting them with community support groups.

It demands a complete synthesis of everything we've discussed today.

To be an effective APN, you have to understand the cellular permeability of the squamacolumbar junction just as deeply as you understand the psychological and emotional trauma of an HIV diagnosis.

And that beautifully ties together the immense scope of Chapter 52.

But before we sign off, we want to leave you with one final thought to mull over as you head into your clinical rotations.

Always something to think about.

We've talked extensively about the delicate balance of the vaginal microbiome, and we just explored the calculated compromises public health officials are already making with oral E .P .T.

for gonorrhea.

What happens to our standard clinical guidelines when antimicrobial resistance reaches a point where these pathogens fully outsmart our single dose therapies?

It's a scary thought.

It is no longer just a theoretical textbook question,

it is a very real looming crisis that you will absolutely be dealing with firsthand in your careers.

It will be the defining clinical challenge for the next generation of advanced practice nurses.

We hope this deep dive helped clarify the complex, invisible landscape of STIs and strengthened your clinical reasoning.

From everyone here at the Last Minute Lecture Team, thank you so much for joining us.

We wish you the absolute best of luck on your upcoming exams and throughout your clinical rotations.

You've got this.

Keep learning, and we will see you next time.